Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
17 déc. 2023 08h01 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds Acelyrin investors of a class action lawsuit and upcoming deadline.
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing
13 déc. 2023 07h00 HE
|
EvolveImmune
Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
11 déc. 2023 02h00 HE
|
Glycotope
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform Berlin, Germany, 11 December 2023 – Glycotope GmbH (Glycotope) has signed...
SLRN Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
07 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
07 déc. 2023 04h00 HE
|
Rentschler Biopharma SE
LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United Kingdom, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO)...
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference
05 déc. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
04 déc. 2023 07h00 HE
|
Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that...
Monthly information on share capital and company voting rights
01 déc. 2023 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Particle Size Analysis Market worth $596 million | MarketsandMarkets.
30 nov. 2023 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Particle Size Analysis Market in terms of revenue was estimated to be worth $446 million in 2023 and is poised to reach $596 million by 2028, growing at a...
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
29 nov. 2023 19h59 HE
|
Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study...